PedAM
Pediatric Disease Annotations & Medicines
| hyperglycemia | ||||
| Disease ID | 710 |
|---|---|
| Disease | hyperglycemia |
| Manually Symptom | (Waiting for update.) |
| Text Mined Symptom | UMLS | Name | Sentences' Count(Total Symptoms:23) C0011847 | diabetes | 382 C0011849 | diabetes mellitus | 78 C0020459 | hyperinsulinemia | 32 C1393529 | vascular complications | 32 C0270739 | hemichorea | 11 C0856169 | endothelial dysfunction | 11 C0009450 | infection | 9 C0948008 | ischemic stroke | 7 C0020538 | hypertension | 7 C0011854 | type 1 diabetes mellitus | 5 C0017979 | glycosuria | 4 C0271672 | diabetic complications | 4 C0008489 | chorea | 3 C0746556 | metabolic disturbance | 3 C0011175 | dehydration | 3 C0011881 | diabetic nephropathy | 3 C0001125 | lactic acidosis | 2 C0010068 | coronary artery disease | 2 C0221169 | hemiballismus | 1 C0020625 | hyponatremia | 1 C0026650 | movement disorders | 1 C0019080 | hemorrhage | 1 C0013949 | embryopathy | 1 |
Manually Genotype(Total Text Mining Genotypes:0) |
|---|
| (Waiting for update.) |
All Snps(Total Genotypes:42) | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| snpId | pubmedId | geneId | geneSymbol | diseaseId | sourceId | sentence | score | Year | geneSymbol_dbSNP | CHROMOSOME | POS | REF | ALT |
| rs10010131 | 18853134 | 6934 | TCF7L2 | umls:C0020456 | BeFree | Polymorphisms in TCF7L2 (rs7903146, OR 1.10, 95% CI 1.04-1.17, p = 0.00097), FTO (rs9939609, OR 1.08, 95% CI 1.02-1.14, p = 0.0065), WFS1 (rs10010131, OR 1.07, 95% CI 1.02-1.13, p = 0.0078) and IGF2BP2 (rs4402960, OR 1.07, 95% CI 1.01-1.13, p = 0.021) predicted the development of at least three components of the metabolic syndrome in both univariate and multivariate analysis; in the case of TCF7L2, WFS1 and IGF2BP this was due to their association with hyperglycaemia (p < 0.00001, p = 0.0033 and p = 0.027, respectively) and for FTO it was due to its association with obesity (p = 0.004). | 0.011996981 | 2008 | WFS1 | 4 | 6291188 | A | G |
| rs10010131 | 18853134 | 10644 | IGF2BP2 | umls:C0020456 | BeFree | Polymorphisms in TCF7L2 (rs7903146, OR 1.10, 95% CI 1.04-1.17, p = 0.00097), FTO (rs9939609, OR 1.08, 95% CI 1.02-1.14, p = 0.0065), WFS1 (rs10010131, OR 1.07, 95% CI 1.02-1.13, p = 0.0078) and IGF2BP2 (rs4402960, OR 1.07, 95% CI 1.01-1.13, p = 0.021) predicted the development of at least three components of the metabolic syndrome in both univariate and multivariate analysis; in the case of TCF7L2, WFS1 and IGF2BP this was due to their association with hyperglycaemia (p < 0.00001, p = 0.0033 and p = 0.027, respectively) and for FTO it was due to its association with obesity (p = 0.004). | 0.002638474 | 2008 | WFS1 | 4 | 6291188 | A | G |
| rs10010131 | 18853134 | 7466 | WFS1 | umls:C0020456 | BeFree | Polymorphisms in TCF7L2 (rs7903146, OR 1.10, 95% CI 1.04-1.17, p = 0.00097), FTO (rs9939609, OR 1.08, 95% CI 1.02-1.14, p = 0.0065), WFS1 (rs10010131, OR 1.07, 95% CI 1.02-1.13, p = 0.0078) and IGF2BP2 (rs4402960, OR 1.07, 95% CI 1.01-1.13, p = 0.021) predicted the development of at least three components of the metabolic syndrome in both univariate and multivariate analysis; in the case of TCF7L2, WFS1 and IGF2BP this was due to their association with hyperglycaemia (p < 0.00001, p = 0.0033 and p = 0.027, respectively) and for FTO it was due to its association with obesity (p = 0.004). | 0.000271442 | 2008 | WFS1 | 4 | 6291188 | A | G |
| rs11708067 | 25793868 | 111 | ADCY5 | umls:C0020456 | BeFree | We measured ADCY5 mRNA expression in paired samples of visceral and subcutaneous adipose tissue from 244 individuals with a wide range of body weight and parameters of hyperglycemia, which have been genotyped for rs11708067. | 0.000271442 | 2015 | ADCY5 | 3 | 123346931 | A | G |
| rs1260326 | 18556336 | 2645 | GCK | umls:C0020456 | BeFree | Moreover, an additive effect of GCKR rs1260326(T) and GCK (-30G) alleles conferred lower fasting glycemia (P = 1 x 10(-13)), insulinemia (P = 5 x 10(-6)), and hyperglycemia risk (P = 1 x 10(-6)). | 0.15627486 | 2008 | GCKR | 2 | 27508073 | T | C |
| rs1260326 | 18556336 | 2646 | GCKR | umls:C0020456 | BeFree | Moreover, an additive effect of GCKR rs1260326(T) and GCK (-30G) alleles conferred lower fasting glycemia (P = 1 x 10(-13)), insulinemia (P = 5 x 10(-6)), and hyperglycemia risk (P = 1 x 10(-6)). | 0.001357209 | 2008 | GCKR | 2 | 27508073 | T | C |
| rs13412852 | 22157924 | 80339 | PNPLA3 | umls:C0020456 | BeFree | The negative association between rs13412852 TT genotype and fibrosis was independent of Patatin-like phospholipase domain-containing-3 genotype and other clinical risk factors, including age, waist circumference, the presence of hyperglycemia, and alanine transaminase levels (OR 0.29; 95% CI 0.11-0.66), and it was confirmed at multivariate analysis in adults (OR 0.15; 95% CI 0.02-0.67). | 0.000271442 | 2012 | LPIN1 | 2 | 11774815 | C | T |
| rs137853240 | 16241915 | 6927 | HNF1A | umls:C0020456 | BeFree | The adjusted odds ratio (OR) and 95% confidence interval for Type 2 diabetes among subjects who carried the HNF1A G319S mutation and had the modified metabolic syndrome (excluding hyperglycaemia) was 20.3 (6.94, 59.6). | 0.005081451 | 2005 | HNF1A | 12 | 120994405 | G | A |
| rs1799983 | 21844127 | 1636 | ACE | umls:C0020456 | BeFree | Effects of human endothelial gene polymorphisms on cellular responses to hyperglycaemia: role of NOS3 (Glu298Asp) and ACE (I/D) polymorphisms. | 0.004267125 | 2011 | NOS3 | 7 | 150999023 | T | G |
| rs1799983 | 16919532 | 4846 | NOS3 | umls:C0020456 | BeFree | The eNOS G894T polymorphism appears to be predictive of persistent hyperglycemia in Chinese subjects with IGT. | 0.126991475 | 2006 | NOS3 | 7 | 150999023 | T | G |
| rs1799983 | 21844127 | 4846 | NOS3 | umls:C0020456 | BeFree | Effects of human endothelial gene polymorphisms on cellular responses to hyperglycaemia: role of NOS3 (Glu298Asp) and ACE (I/D) polymorphisms. | 0.126991475 | 2011 | NOS3 | 7 | 150999023 | T | G |
| rs1800797 | 20080841 | 28411 | IGHV3-71 | umls:C0020456 | BeFree | Possession of the IL-6 rs1800797 GG genotype by the LTA and TNF-alpha risk genotype carriers further increased risk of the MetS [OR 2.10 (CI 1.19-3.71) P = 0.009], fasting hyperglycemia [OR 2.65 (CI 1.12-6.28), P = 0.027], high systolic blood pressure [OR 1.99 (CI 1.07-3.72), P = 0.03], and abdominal obesity [OR 1.52 (CI 1.01-2.28), P = 0.04]. | 0.000271442 | 2010 | IL6;LOC541472 | 7 | 22726602 | A | G |
| rs1801282 | 16567542 | 9370 | ADIPOQ | umls:C0020456 | BeFree | The PPARG Pro12Ala polymorphism is associated with a decreased risk of developing hyperglycemia over 6 years and combines with the effect of the APM1 G-11391A single nucleotide polymorphism: the Data From an Epidemiological Study on the Insulin Resistance Syndrome (DESIR) study. | 0.003452799 | 2006 | PPARG | 3 | 12351626 | C | G |
| rs1801282 | 16567542 | 5468 | PPARG | umls:C0020456 | BeFree | The PPARG Pro12Ala polymorphism is associated with a decreased risk of developing hyperglycemia over 6 years and combines with the effect of the APM1 G-11391A single nucleotide polymorphism: the Data From an Epidemiological Study on the Insulin Resistance Syndrome (DESIR) study. | 0.009358507 | 2006 | PPARG | 3 | 12351626 | C | G |
| rs1801282 | 16567542 | 201501 | ZBTB7C | umls:C0020456 | BeFree | The PPARG Pro12Ala polymorphism is associated with a decreased risk of developing hyperglycemia over 6 years and combines with the effect of the APM1 G-11391A single nucleotide polymorphism: the Data From an Epidemiological Study on the Insulin Resistance Syndrome (DESIR) study. | 0.000271442 | 2006 | PPARG | 3 | 12351626 | C | G |
| rs1805192 | 16567542 | 5468 | PPARG | umls:C0020456 | BeFree | The PPARG Pro12Ala polymorphism is associated with a decreased risk of developing hyperglycemia over 6 years and combines with the effect of the APM1 G-11391A single nucleotide polymorphism: the Data From an Epidemiological Study on the Insulin Resistance Syndrome (DESIR) study. | 0.009358507 | 2006 | PPARG | 3 | 12379739 | C | G |
| rs1805192 | 16567542 | 201501 | ZBTB7C | umls:C0020456 | BeFree | The PPARG Pro12Ala polymorphism is associated with a decreased risk of developing hyperglycemia over 6 years and combines with the effect of the APM1 G-11391A single nucleotide polymorphism: the Data From an Epidemiological Study on the Insulin Resistance Syndrome (DESIR) study. | 0.000271442 | 2006 | PPARG | 3 | 12379739 | C | G |
| rs1805192 | 16567542 | 9370 | ADIPOQ | umls:C0020456 | BeFree | The PPARG Pro12Ala polymorphism is associated with a decreased risk of developing hyperglycemia over 6 years and combines with the effect of the APM1 G-11391A single nucleotide polymorphism: the Data From an Epidemiological Study on the Insulin Resistance Syndrome (DESIR) study. | 0.003452799 | 2006 | PPARG | 3 | 12379739 | C | G |
| rs193922289 | 19187021 | 2645 | GCK | umls:C0020456 | BeFree | The glucokinase V62M and G72R mutations are naturally occurring and known to associate with hyperglycemia in humans. | 0.15627486 | 2009 | GCK | 7 | 44152420 | C | T |
| rs386597997 | 12196481 | 3767 | KCNJ11 | umls:C0020456 | BeFree | The prevalent Glu23Lys polymorphism in the potassium inward rectifier 6.2 (KIR6.2) gene is associated with impaired glucagon suppression in response to hyperglycemia. | 0.013807317 | 2002 | NA | NA | NA | NA | NA |
| rs386597997 | 12196481 | 2641 | GCG | umls:C0020456 | BeFree | The prevalent Glu23Lys polymorphism in the potassium inward rectifier 6.2 (KIR6.2) gene is associated with impaired glucagon suppression in response to hyperglycemia. | 0.126786047 | 2002 | NA | NA | NA | NA | NA |
| rs397514580 | 21104275 | 2645 | GCK | umls:C0020456 | BeFree | In the present study, we identified and functionally characterized a novel missense mutation in the GCK gene, which results in a protein mutation Glu(339)→Lys (E339K), from a Chinese family with hyperglycemia. | 0.15627486 | 2011 | GCK;LOC105375258 | 7 | 44146467 | C | T |
| rs4402960 | 18853134 | 10644 | IGF2BP2 | umls:C0020456 | BeFree | Polymorphisms in TCF7L2 (rs7903146, OR 1.10, 95% CI 1.04-1.17, p = 0.00097), FTO (rs9939609, OR 1.08, 95% CI 1.02-1.14, p = 0.0065), WFS1 (rs10010131, OR 1.07, 95% CI 1.02-1.13, p = 0.0078) and IGF2BP2 (rs4402960, OR 1.07, 95% CI 1.01-1.13, p = 0.021) predicted the development of at least three components of the metabolic syndrome in both univariate and multivariate analysis; in the case of TCF7L2, WFS1 and IGF2BP this was due to their association with hyperglycaemia (p < 0.00001, p = 0.0033 and p = 0.027, respectively) and for FTO it was due to its association with obesity (p = 0.004). | 0.002638474 | 2008 | IGF2BP2 | 3 | 185793899 | G | T |
| rs4402960 | 18853134 | 6934 | TCF7L2 | umls:C0020456 | BeFree | Polymorphisms in TCF7L2 (rs7903146, OR 1.10, 95% CI 1.04-1.17, p = 0.00097), FTO (rs9939609, OR 1.08, 95% CI 1.02-1.14, p = 0.0065), WFS1 (rs10010131, OR 1.07, 95% CI 1.02-1.13, p = 0.0078) and IGF2BP2 (rs4402960, OR 1.07, 95% CI 1.01-1.13, p = 0.021) predicted the development of at least three components of the metabolic syndrome in both univariate and multivariate analysis; in the case of TCF7L2, WFS1 and IGF2BP this was due to their association with hyperglycaemia (p < 0.00001, p = 0.0033 and p = 0.027, respectively) and for FTO it was due to its association with obesity (p = 0.004). | 0.011996981 | 2008 | IGF2BP2 | 3 | 185793899 | G | T |
| rs4402960 | 18853134 | 7466 | WFS1 | umls:C0020456 | BeFree | Polymorphisms in TCF7L2 (rs7903146, OR 1.10, 95% CI 1.04-1.17, p = 0.00097), FTO (rs9939609, OR 1.08, 95% CI 1.02-1.14, p = 0.0065), WFS1 (rs10010131, OR 1.07, 95% CI 1.02-1.13, p = 0.0078) and IGF2BP2 (rs4402960, OR 1.07, 95% CI 1.01-1.13, p = 0.021) predicted the development of at least three components of the metabolic syndrome in both univariate and multivariate analysis; in the case of TCF7L2, WFS1 and IGF2BP this was due to their association with hyperglycaemia (p < 0.00001, p = 0.0033 and p = 0.027, respectively) and for FTO it was due to its association with obesity (p = 0.004). | 0.000271442 | 2008 | IGF2BP2 | 3 | 185793899 | G | T |
| rs5219 | 12196481 | 2641 | GCG | umls:C0020456 | BeFree | The prevalent Glu23Lys polymorphism in the potassium inward rectifier 6.2 (KIR6.2) gene is associated with impaired glucagon suppression in response to hyperglycemia. | 0.126786047 | 2002 | KCNJ11 | 11 | 17388025 | T | C |
| rs5219 | 12196481 | 3767 | KCNJ11 | umls:C0020456 | BeFree | The prevalent Glu23Lys polymorphism in the potassium inward rectifier 6.2 (KIR6.2) gene is associated with impaired glucagon suppression in response to hyperglycemia. | 0.013807317 | 2002 | KCNJ11 | 11 | 17388025 | T | C |
| rs59852838 | 18346985 | 3630 | INS | umls:C0020456 | BeFree | A mutation in ABCC8/SUR1, leading to a Y356C substitution in the seventh membrane-spanning alpha-helix, was observed in a patient diagnosed with hyperglycemia at age 39 years and in two adult offspring with impaired insulin secretion. | 0.273560747 | 2008 | ABCC8 | 11 | 17453228 | T | C |
| rs59852838 | 18346985 | 6833 | ABCC8 | umls:C0020456 | BeFree | A mutation in ABCC8/SUR1, leading to a Y356C substitution in the seventh membrane-spanning alpha-helix, was observed in a patient diagnosed with hyperglycemia at age 39 years and in two adult offspring with impaired insulin secretion. | 0.001628651 | 2008 | ABCC8 | 11 | 17453228 | T | C |
| rs671 | 25263942 | 217 | ALDH2 | umls:C0020456 | BeFree | Furthermore, the ALDH2 Glu504Lys polymorphism has been shown to be associated with certain traditional cardiovascular risk factors, such as dyslipidemia, hypertension, and diabetes mellitus or hyperglycemia. | 0.000542884 | 2015 | ALDH2 | 12 | 111803962 | G | A |
| rs7903146 | 19183934 | 3630 | INS | umls:C0020456 | BeFree | We confirmed that the risk allele of rs7903146 is associated with hyperglycaemia and a higher proinsulin/insulin ratio. | 0.273560747 | 2009 | TCF7L2 | 10 | 112998590 | C | T |
| rs7903146 | 18853134 | 6934 | TCF7L2 | umls:C0020456 | BeFree | Polymorphisms in TCF7L2 (rs7903146, OR 1.10, 95% CI 1.04-1.17, p = 0.00097), FTO (rs9939609, OR 1.08, 95% CI 1.02-1.14, p = 0.0065), WFS1 (rs10010131, OR 1.07, 95% CI 1.02-1.13, p = 0.0078) and IGF2BP2 (rs4402960, OR 1.07, 95% CI 1.01-1.13, p = 0.021) predicted the development of at least three components of the metabolic syndrome in both univariate and multivariate analysis; in the case of TCF7L2, WFS1 and IGF2BP this was due to their association with hyperglycaemia (p < 0.00001, p = 0.0033 and p = 0.027, respectively) and for FTO it was due to its association with obesity (p = 0.004). | 0.011996981 | 2008 | TCF7L2 | 10 | 112998590 | C | T |
| rs7903146 | 17065361 | 3630 | INS | umls:C0020456 | BeFree | We conclude that the TCF7L2 T at-risk allele variation (rs7903146) predicts hyperglycemia incidence in a general French population, possibly through a deleterious effect on insulin secretion. | 0.273560747 | 2006 | TCF7L2 | 10 | 112998590 | C | T |
| rs7903146 | 18853134 | 10644 | IGF2BP2 | umls:C0020456 | BeFree | Polymorphisms in TCF7L2 (rs7903146, OR 1.10, 95% CI 1.04-1.17, p = 0.00097), FTO (rs9939609, OR 1.08, 95% CI 1.02-1.14, p = 0.0065), WFS1 (rs10010131, OR 1.07, 95% CI 1.02-1.13, p = 0.0078) and IGF2BP2 (rs4402960, OR 1.07, 95% CI 1.01-1.13, p = 0.021) predicted the development of at least three components of the metabolic syndrome in both univariate and multivariate analysis; in the case of TCF7L2, WFS1 and IGF2BP this was due to their association with hyperglycaemia (p < 0.00001, p = 0.0033 and p = 0.027, respectively) and for FTO it was due to its association with obesity (p = 0.004). | 0.002638474 | 2008 | TCF7L2 | 10 | 112998590 | C | T |
| rs7903146 | 22461567 | 2641 | GCG | umls:C0020456 | BeFree | Diabetes-associated variation (T allele at rs7903146) in TCF7L2 may impair the ability of hyperglycemia to suppress glucagon (45 ± 2 vs. 47 ± 2 vs. 60 ± 5 ng/L for CC, CT, and TT, respectively, P = 0.02). | 0.126786047 | 2012 | TCF7L2 | 10 | 112998590 | C | T |
| rs7903146 | 22461567 | 6934 | TCF7L2 | umls:C0020456 | BeFree | Diabetes-associated variation (T allele at rs7903146) in TCF7L2 may impair the ability of hyperglycemia to suppress glucagon (45 ± 2 vs. 47 ± 2 vs. 60 ± 5 ng/L for CC, CT, and TT, respectively, P = 0.02). | 0.011996981 | 2012 | TCF7L2 | 10 | 112998590 | C | T |
| rs7903146 | 18853134 | 7466 | WFS1 | umls:C0020456 | BeFree | Polymorphisms in TCF7L2 (rs7903146, OR 1.10, 95% CI 1.04-1.17, p = 0.00097), FTO (rs9939609, OR 1.08, 95% CI 1.02-1.14, p = 0.0065), WFS1 (rs10010131, OR 1.07, 95% CI 1.02-1.13, p = 0.0078) and IGF2BP2 (rs4402960, OR 1.07, 95% CI 1.01-1.13, p = 0.021) predicted the development of at least three components of the metabolic syndrome in both univariate and multivariate analysis; in the case of TCF7L2, WFS1 and IGF2BP this was due to their association with hyperglycaemia (p < 0.00001, p = 0.0033 and p = 0.027, respectively) and for FTO it was due to its association with obesity (p = 0.004). | 0.000271442 | 2008 | TCF7L2 | 10 | 112998590 | C | T |
| rs80356671 | 14610263 | 3630 | INS | umls:C0020456 | BeFree | The Akita mouse with a missense mutation (Cys96Tyr) in the insulin 2 gene has hyperglycemia and a reduced beta-cell mass. | 0.273560747 | 2003 | INS;INS-IGF2 | 11 | 2159898 | C | T,G |
| rs8066560 | 24825092 | 6720 | SREBF1 | umls:C0020456 | BeFree | Association of rs8066560 variant in the sterol regulatory element-binding protein 1 (SREBP-1) and miR-33b genes with hyperglycemia and insulin resistance. | 0.000271442 | 2014 | SREBF1 | 17 | 17824729 | A | G |
| rs9939609 | 18853134 | 6934 | TCF7L2 | umls:C0020456 | BeFree | Polymorphisms in TCF7L2 (rs7903146, OR 1.10, 95% CI 1.04-1.17, p = 0.00097), FTO (rs9939609, OR 1.08, 95% CI 1.02-1.14, p = 0.0065), WFS1 (rs10010131, OR 1.07, 95% CI 1.02-1.13, p = 0.0078) and IGF2BP2 (rs4402960, OR 1.07, 95% CI 1.01-1.13, p = 0.021) predicted the development of at least three components of the metabolic syndrome in both univariate and multivariate analysis; in the case of TCF7L2, WFS1 and IGF2BP this was due to their association with hyperglycaemia (p < 0.00001, p = 0.0033 and p = 0.027, respectively) and for FTO it was due to its association with obesity (p = 0.004). | 0.011996981 | 2008 | FTO | 16 | 53786615 | T | A |
| rs9939609 | 18853134 | 10644 | IGF2BP2 | umls:C0020456 | BeFree | Polymorphisms in TCF7L2 (rs7903146, OR 1.10, 95% CI 1.04-1.17, p = 0.00097), FTO (rs9939609, OR 1.08, 95% CI 1.02-1.14, p = 0.0065), WFS1 (rs10010131, OR 1.07, 95% CI 1.02-1.13, p = 0.0078) and IGF2BP2 (rs4402960, OR 1.07, 95% CI 1.01-1.13, p = 0.021) predicted the development of at least three components of the metabolic syndrome in both univariate and multivariate analysis; in the case of TCF7L2, WFS1 and IGF2BP this was due to their association with hyperglycaemia (p < 0.00001, p = 0.0033 and p = 0.027, respectively) and for FTO it was due to its association with obesity (p = 0.004). | 0.002638474 | 2008 | FTO | 16 | 53786615 | T | A |
| rs9939609 | 18853134 | 7466 | WFS1 | umls:C0020456 | BeFree | Polymorphisms in TCF7L2 (rs7903146, OR 1.10, 95% CI 1.04-1.17, p = 0.00097), FTO (rs9939609, OR 1.08, 95% CI 1.02-1.14, p = 0.0065), WFS1 (rs10010131, OR 1.07, 95% CI 1.02-1.13, p = 0.0078) and IGF2BP2 (rs4402960, OR 1.07, 95% CI 1.01-1.13, p = 0.021) predicted the development of at least three components of the metabolic syndrome in both univariate and multivariate analysis; in the case of TCF7L2, WFS1 and IGF2BP this was due to their association with hyperglycaemia (p < 0.00001, p = 0.0033 and p = 0.027, respectively) and for FTO it was due to its association with obesity (p = 0.004). | 0.000271442 | 2008 | FTO | 16 | 53786615 | T | A |
GWASdb Annotation(Total Genotypes:0) | |
|---|---|
| (Waiting for update.) | |
GWASdb Snp Trait(Total Genotypes:0) | |
|---|---|
| (Waiting for update.) | |
Mapped by lexical matching(Total Items:0) |
|---|
| (Waiting for update.) |
Mapped by homologous gene(Total Items:0) |
|---|
| (Waiting for update.) |
Chemical(Total Drugs:41) | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| CUI | ChemicalName | ChemicalID | CasRN | DiseaseName | DiseaseID | DirectEvidence | PubMedIDs | ||
| C0020456 | acarbose | D020909 | 56180-94-0 | hyperglycemia | MESH:D006943 | therapeutic | 20667563 | ||
| C0020456 | acetylcysteine | D000111 | 616-91-1 | hyperglycemia | MESH:D006943 | therapeutic | 16814277 | ||
| C0020456 | aminocaproic acid | D015119 | 60-32-2 | hyperglycemia | MESH:D006943 | marker/mechanism | 1117341 | ||
| C0020456 | arsenic trioxide | C006632 | 1327-53-3 | hyperglycemia | MESH:D006943 | marker/mechanism | 25859628 | ||
| C0020456 | atropine | D001285 | 51-55-8 | hyperglycemia | MESH:D006943 | therapeutic | 22305719 | ||
| C0020456 | benazepril | C044946 | 86541-75-5 | hyperglycemia | MESH:D006943 | therapeutic | 11798618 | ||
| C0020456 | betamethasone | D001623 | 378-44-9 | hyperglycemia | MESH:D006943 | marker/mechanism | 19249894 | ||
| C0020456 | biotin | D001710 | 58-85-5 | hyperglycemia | MESH:D006943 | therapeutic | 17496732 | ||
| C0020456 | capsaicin | D002211 | 404-86-4 | hyperglycemia | MESH:D006943 | therapeutic | 1378463 | ||
| C0020456 | cimetidine | D002927 | 51481-61-9 | hyperglycemia | MESH:D006943 | marker/mechanism | 85850 | ||
| C0020456 | clonidine | D003000 | 4205-90-7 | hyperglycemia | MESH:D006943 | marker/mechanism | 3513563 | ||
| C0020456 | clozapine | D003024 | 5786-21-0 | hyperglycemia | MESH:D006943 | marker/mechanism | 11125862 | ||
| C0020456 | desoximetasone | D003899 | 382-67-2 | hyperglycemia | MESH:D006943 | marker/mechanism | 18591846 | ||
| C0020456 | doxycycline | D004318 | 564-25-0 | hyperglycemia | MESH:D006943 | marker/mechanism | 9145823 | ||
| C0020456 | enalapril | D004656 | 75847-73-3 | hyperglycemia | MESH:D006943 | marker/mechanism | 9861226 | ||
| C0020456 | enalapril | D004656 | 75847-73-3 | hyperglycemia | MESH:D006943 | therapeutic | 8591707 | ||
| C0020456 | everolimus | D000068338 | - | hyperglycemia | MESH:D006943 | marker/mechanism | 16951235 | ||
| C0020456 | indinavir | D019469 | 150378-17-9 | hyperglycemia | MESH:D006943 | marker/mechanism | 12473836 | ||
| C0020456 | metformin | D008687 | 657-24-9 | hyperglycemia | MESH:D006943 | therapeutic | 14984458 | ||
| C0020456 | methadone | D008691 | 76-99-3 | hyperglycemia | MESH:D006943 | marker/mechanism | 2554359 | ||
| C0020456 | metoprolol | D008790 | 37350-58-6 | hyperglycemia | MESH:D006943 | marker/mechanism | 3513563 | ||
| C0020456 | miglitol | C045621 | - | hyperglycemia | MESH:D006943 | therapeutic | 20667563 | ||
| C0020456 | octreotide | D015282 | 83150-76-9 | hyperglycemia | MESH:D006943 | marker/mechanism | 17897286 | ||
| C0020456 | ofloxacin | D015242 | 82419-36-1 | hyperglycemia | MESH:D006943 | marker/mechanism | 17026994 | ||
| C0020456 | olanzapine | C076029 | 132539-06-1 | hyperglycemia | MESH:D006943 | marker/mechanism | 11927762 | ||
| C0020456 | paclitaxel | D017239 | - | hyperglycemia | MESH:D006943 | marker/mechanism | 15493358 | ||
| C0020456 | phenytoin | D010672 | 57-41-0 | hyperglycemia | MESH:D006943 | marker/mechanism | 5763660 | ||
| C0020456 | propranolol | D011433 | 525-66-6 | hyperglycemia | MESH:D006943 | marker/mechanism | 1032269 | ||
| C0020456 | propranolol | D011433 | 525-66-6 | hyperglycemia | MESH:D006943 | therapeutic | 22305719 | ||
| C0020456 | pyruvic acid | D019289 | 127-17-3 | hyperglycemia | MESH:D006943 | marker/mechanism | 19819963 | ||
| C0020456 | rifampin | D012293 | 13292-46-1 | hyperglycemia | MESH:D006943 | marker/mechanism | 23588309 | ||
| C0020456 | ritonavir | D019438 | - | hyperglycemia | MESH:D006943 | marker/mechanism | 12473836 | ||
| C0020456 | rosiglitazone | C089730 | - | hyperglycemia | MESH:D006943 | therapeutic | 16757903 | ||
| C0020456 | sirolimus | D020123 | 53123-88-9 | hyperglycemia | MESH:D006943 | marker/mechanism | 20358864 | ||
| C0020456 | sotalol | D013015 | 3930-20-9 | hyperglycemia | MESH:D006943 | therapeutic | 1032269 | ||
| C0020456 | streptozocin | D013311 | 18883-66-4 | hyperglycemia | MESH:D006943 | marker/mechanism | 10052637 | ||
| C0020456 | tacrolimus | D016559 | 109581-93-3 | hyperglycemia | MESH:D006943 | marker/mechanism | 10616519 | ||
| C0020456 | temsirolimus | C401859 | - | hyperglycemia | MESH:D006943 | marker/mechanism | 20430774 | ||
| C0020456 | theophylline | D013806 | 58-55-9 | hyperglycemia | MESH:D006943 | marker/mechanism | 1445173 | ||
| C0020456 | troglitazone | C057693 | 97322-87-7 | hyperglycemia | MESH:D006943 | therapeutic | 11231916 | ||
| C0020456 | valproic acid | D014635 | 99-66-1 | hyperglycemia | MESH:D006943 | marker/mechanism | 12773089 | ||
FDA approved drug and dosage information(Total Drugs:12) | ||||||||
|---|---|---|---|---|---|---|---|---|
| DiseaseID | Drug_name | active_ingredients | strength | Dosage Form/Route | Marketing Status | TE code | RLD | RS |
| MESH:D006943 | rapamune | sirolimus | 1MG/ML | SOLUTION;ORAL | Prescription | None | Yes | Yes |
| MESH:D006943 | rapamune | sirolimus | 1MG | TABLET;ORAL | Prescription | AB | Yes | No |
| MESH:D006943 | norvir | ritonavir | 80MG/ML | SOLUTION;ORAL | Prescription | None | Yes | Yes |
| MESH:D006943 | norvir | ritonavir | 100MG | CAPSULE;ORAL | Discontinued | None | No | No |
| MESH:D006943 | norvir | ritonavir | 100MG | CAPSULE;ORAL | Prescription | None | Yes | Yes |
| MESH:D006943 | norvir | ritonavir | 100MG | TABLET;ORAL | Prescription | AB | Yes | Yes |
| MESH:D006943 | zyprexa | olanzapine | 2.5MG | TABLET;ORAL | Prescription | AB | Yes | No |
| MESH:D006943 | zyprexa | olanzapine | 10MG/VIAL | INJECTABLE;INTRAMUSCULAR | Prescription | AP | Yes | Yes |
| MESH:D006943 | zyprexa | olanzapine | 2.5MG | TABLET;ORAL | Prescription | AB | Yes | No |
| MESH:D006943 | zyprexa | olanzapine | 10MG/VIAL | INJECTABLE;INTRAMUSCULAR | Prescription | AP | Yes | Yes |
| MESH:D006943 | afinitor | everolimus | 5MG | TABLET;ORAL | Prescription | None | Yes | No |
| MESH:D006943 | torisel | temsirolimus | 25MG/ML (25MG/ML) | SOLUTION;INTRAVENOUS | Prescription | None | Yes | Yes |
FDA labeling changes(Total Drugs:12) | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| DiseaseID | Pediatric_Labeling_Date | Trade_Name | Generic_Name_or_Proper_Name | Indications Studied | Label Changes Summary | Product Labeling | BPCA(B) | PREA(P) | BPCA(B) and PREA(P) | Pediatric Rule (R) | Sponsor | Pediatric Exclusivity Granted Date | NNPS |
| MESH:D006943 | 11/3/2005 | rapamune | sirolimus | Prophylaxis of organ rejection in patients undergoing renal transplants | Safety and efficacy established in children 13 years or older judged to be at low to moderate immunologic risk Safety was assessed in a controlled clinical trial in pediatric ( | Labeling | B | - | - | - | Wyeth | 11/17/2004 | FALSE' |
| MESH:D006943 | 11/3/2005 | rapamune | sirolimus | Prophylaxis of organ rejection in patients undergoing renal transplants | Safety and efficacy established in children 13 years or older judged to be at low to moderate immunologic risk Safety was assessed in a controlled clinical trial in pediatric ( | Labeling | B | - | - | - | Wyeth | 11/17/2004 | FALSE' |
| MESH:D006943 | 6/10/2005 | norvir | ritonavir | Treatment of HIV-infection in combination with other antiretroviral agents | Extended age range from 2 years down to 1 month AE profile in the pediatric population was similar to that for adults Information on dose and PK parameters | Labeling | B | - | - | - | Abbott | 06/14/2005 | FALSE' |
| MESH:D006943 | 6/10/2005 | norvir | ritonavir | Treatment of HIV-infection in combination with other antiretroviral agents | Extended age range from 2 years down to 1 month AE profile in the pediatric population was similar to that for adults Information on dose and PK parameters | Labeling | B | - | - | - | Abbott | 06/14/2005 | FALSE' |
| MESH:D006943 | 6/10/2005 | norvir | ritonavir | Treatment of HIV-infection in combination with other antiretroviral agents | Extended age range from 2 years down to 1 month AE profile in the pediatric population was similar to that for adults Information on dose and PK parameters | Labeling | B | - | - | - | Abbott | 06/14/2005 | FALSE' |
| MESH:D006943 | 6/10/2005 | norvir | ritonavir | Treatment of HIV-infection in combination with other antiretroviral agents | Extended age range from 2 years down to 1 month AE profile in the pediatric population was similar to that for adults Information on dose and PK parameters | Labeling | B | - | - | - | Abbott | 06/14/2005 | FALSE' |
| MESH:D006943 | 08/14/2008 | zyprexa | olanzapine | schizophrenia; bipolar disorder | Safety and effectiveness have not been established for patients less than 18 years of age In an analysis of placebo-controlled olanzapine monotherapy studies of adolescent patients, including those with schizophrenia or bipolar disorder, olanzapine was associated with: oHyperglycemia - a statistically significantly greater mean change in fasting glucose levels compared to placebo oHyperlipidemia statistically significant increases compared to placebo in fasting triglycerides, fasting total cholesterol and fasting LDL cholesterol oWeight gain olanzapine treated patients gained an average of 4.6 kg, compared to an average of 0.3 kg in placebo-treated patients with a median exposure of 3 weeks; Average weight gain during long-term therapy was 7.4 kg | - | B | - | - | - | Lilly | 10/1/2007 | FALSE' |
| MESH:D006943 | 08/14/2008 | zyprexa | olanzapine | schizophrenia; bipolar disorder | Safety and effectiveness have not been established for patients less than 18 years of age In an analysis of placebo-controlled olanzapine monotherapy studies of adolescent patients, including those with schizophrenia or bipolar disorder, olanzapine was associated with: oHyperglycemia - a statistically significantly greater mean change in fasting glucose levels compared to placebo oHyperlipidemia statistically significant increases compared to placebo in fasting triglycerides, fasting total cholesterol and fasting LDL cholesterol oWeight gain olanzapine treated patients gained an average of 4.6 kg, compared to an average of 0.3 kg in placebo-treated patients with a median exposure of 3 weeks; Average weight gain during long-term therapy was 7.4 kg | - | B | - | - | - | Lilly | 10/1/2007 | FALSE' |
| MESH:D006943 | 4/12/2009 | zyprexa | olanzapine | Treatment of manic or mixed episodes of bipolar I disorder and schizophrenia in adolescents ages 13-17 | Extended schizophrenia and manic or mixed episodes of bipolar I disorder indications from adults to adolescents 1317 years of age Safety and effectiveness in children < 13 years of age have not been established Recommended starting dose for adolescents is lower than that for adults Compared to patients from adult clinical trials, adolescents were likely to gain more weight, experience increased sedation, and have greater increases in total cholesterol, triglycerides, LDL cholesterol, prolactin and hepatic transaminase levels Information on dosing, adverse reactions, pharmacokinetics, clinical studies | Labeling | B | - | - | - | Lilly | 10/1/2007 | TRUE' |
| MESH:D006943 | 4/12/2009 | zyprexa | olanzapine | Treatment of manic or mixed episodes of bipolar I disorder and schizophrenia in adolescents ages 13-17 | Extended schizophrenia and manic or mixed episodes of bipolar I disorder indications from adults to adolescents 1317 years of age Safety and effectiveness in children < 13 years of age have not been established Recommended starting dose for adolescents is lower than that for adults Compared to patients from adult clinical trials, adolescents were likely to gain more weight, experience increased sedation, and have greater increases in total cholesterol, triglycerides, LDL cholesterol, prolactin and hepatic transaminase levels Information on dosing, adverse reactions, pharmacokinetics, clinical studies | Labeling | B | - | - | - | Lilly | 10/1/2007 | TRUE' |
| MESH:D006943 | 10/29/2010 | afinitor | everolimus | Treatment of patients with subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis | Approved for treatment of patients with SEGA associated with TS An open-label, single-arm safety and efficacy trial was conducted in 28 patients 3-34 years with SEGA associated with TS Afinitor has not been studied in patients with SEGA < 3 years of ageMost common adverse reactions (incidence e30%) were stomatitis, upper respiratory tract infection, sinusitis, otitis media, and pyrexiaDose reduction and/or treatment interruption may be needed to manage adverse drug reactions Information on starting dose, therapeutic drug monitoring, clinical trial, and adverse reactions New indication | Labeling | B | - | - | - | Novartis | - | FALSE' |
| MESH:D006943 | 05/30/2012 | torisel | temsirolimus | Advanced recurrent/refractory solid tumors | Effectiveness in pediatric patients has not been established Torisel was studied in 59 patients 1 - 17 years and 12 patients 18 to 21 years in a phase 1-2 safety and exploratory pharmacodynamic study Adverse reactions were similar to those observedd in adults Information on dosing, clinical trials and PK parameters | Labeling | B | - | - | - | - | - | FALSE' |